Pathogenesis and Treatment of Leukemia

This book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies.

This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.

 

Comprehensive and up-to-date account on pathogenesis and treatment of acute and chronic leukemias

Wide range of authors and international experts

Text and illustrations suitable for Haematologists, Oncologists, Pathologists, Scientists and graduate students

 

Chapter 1            Basic haematopoiesis and leukemia stem cells

Chapter 2            Modern classification of acute and chronic leukemias: integrating biology, clinicopathologic features and genomics

Chapter 3            Molecular techniques in the diagnosis and monitoring of acute and chronic leukemias

Chapter 4            Flow cytometric techniques in the diagnosis and monitoring of acute leukemias

Chapter 5            Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia

Chapter 6            Frontline management of acute myeloid leukaemia eligible for intensive chemotherapy

Chapter 7            Frontline management of elderly acute myeloid leukemia ineligible for intensive treatment

Chapter 8            Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia

Chapter 9            Management of relapsed or refractory AML

Chapter 10          The Role of BCL-2 / MCL-1 targeting in Acute Myeloid Leukemia

Chapter 11          Role of IDH1/IDH2 inhibitors in AML

Chapter 12          Next-generation FLT3 inhibitors for the treatment of FLT3-positive AML

Chapter 13          Allogeneic hematopoietic stem cell transplantation for AML

Chapter 14          Maintenance therapy following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Chapter 15          Immunotherapeutic targeting of AML

Chapter 16          In the pipeline – Emerging therapy for acute myeloid leukaemia

Chapter 17          Frontline management of acute promyelocytic leukemia

Chapter 18          Management of relapsed acute promyelocyticleukemia and the role of hematopoietic stem cell transplantation

Chapter 19          Genomic Landscape of Acute Lymphoblastic Leukaemia (ALL) – Insights to Leukaemogenesis, Prognostications and Treatment

Chapter 20          Management of adolescent and young adults with Acute Lymphoblastic Leukaemia

Chapter 21          Management of older patients with acute lymphoblastic leukemia

Chapter 22          Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia

Chapter 23            Management of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL)

Chapter 24          Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Chapter 25          Immunotherapy for ALL

Chapter 26          In the Pipeline - Emerging therapy for ALL

Chapter 27          Inherited/genetic predisposition to MDS and AML

Chapter 28          Clonal hematopoiesis and its functional implications in MDS/AML

Chapter 29          Therapy-related MDS/AML and the role of environmental factors

Chapter 30          Prognostic indicators in MDS and CMML

Chapter 31          Treatment algorithm of myelodysplastic syndromes

Chapter 32          Treatment algorithm of CMML and other uncommon MDS/MPN subtypes

Chapter 33          Novel strategies to manage cytopenia in low-risk MDS

Chapter 34          Allogeneic hematopoietic stem cell transplantation for MDS and CMML: when and how?

Chapter 35          In the Pipeline - Emerging therapy for MDS and MDS/MPN

Chapter 36          Molecular landscape and personalized prognostic prediction of MPNs

Chapter 37          Treatment algorithm of polycythemia Vera

Chapter 38          Treatment algorithm of essential thrombocythemia

Chapter 39          Prognostic models for primary and secondary myelofibrosis

Chapter 40          Treatment algorithm for primary and secondary myelofibrosis

Chapter 41          Diagnosis and management of prefibrotic primary myelofibrosis (pre-PMF)

Chapter 42          Interferons In myeloproliferative neoplasms

Chapter 43          JAK inhibitors for the management of myeloproliferative neoplasms

Chapter 44          Allogeneic hematopoietic stem cell transplantation for myelofibrosis – when and how?

Chapter 45          Thrombosis and myeloproliferative neoplasms

Chapter 46          Eosinophilic disorders and systemic mastocytosis

Chapter 47          In the Pipeline - Emerging therapy for classical Ph-negative MPNs

Chapter 48          "Current guidelines and treatment algorithm of

chronic myeloid leukaemia"

Chapter 49          Treatment-free remission in chronic myeloid leukemia

Chapter 50          Treatment options in CML resistant or intolerant to second-generation tyrosine kinase inhibitors

Chapter 51          Allogeneic hematopoietic cell transplantation in CML: when and how?

Chapter 52          In the Pipeline - Emerging therapy for CML

 

Dr. Gill Harinder is principal investigator in the Department of Medicine, Queen Mary Hospital, University of Hong Kong.

Professor Yok-Lam Kwong is Chief of the Division of Haematology, Oncology and Bone Marrow Transplantation at the Department of Medicine, University of Hong Kong.

RECENZII

Spune-ne opinia ta despre acest produs!

scrie o recenzie